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We have identified mutations in Raf-1 that increase
binding to Ras. The mutations were identified making
use of three mutant forms of Ras that have reduced
Raf-1 binding (Winkler, D. G., Johnson, J. C., Cooper,
J. A., and Vojtek, A. B. (1997) J. Biol. Chem. 272, 24402–
24409). One mutation in Raf-1, N64L, suppresses the Ras
mutant R41Q but not other Ras mutants, suggesting that
this mutation structurally complements the Ras R41Q
mutation. Missense substitutions of residues 143 and 144
in the Raf-1 cysteine-rich domain were isolated multiple
times. These Raf-1 mutants, R143Q, R143W, and K144E,
were general suppressors of three different Ras mutants
and had increased interaction with non-mutant Ras.
Each was slightly activated relative to wild-type Raf-1 in
a transformation assay. In addition, two mutants,
R143W and K144E, were active when tested for induc-
tion of germinal vesicle breakdown in Xenopus oocytes.
Interestingly, all three cysteine-rich domain mutations
reduced the ability of the Raf-1 N-terminal regulatory
region to inhibit Xenopus oocyte germinal vesicle break-
down induced by the C-terminal catalytic region of
Raf-1. We propose that a direct or indirect regulatory
interaction between the N- and C-terminal regions of
Raf-1 is reduced by the R143W, R143Q, and K144E mu-
tations, thereby increasing access to the Ras-binding
regions of Raf-1 and increasing Raf-1 activity.
The importance of the Raf protein kinases for cell growth and
differentiation has been demonstrated in animals, tissue cul-
ture cells, Drosophila, and Caenorhabditis elegans. A highly
conserved signal transduction pathway links growth factor re-
ceptors through the Ras small GTP-binding protein to the
activation of the Raf-1 protein kinase. Raf-1 in turn can bind to,
phosphorylate, and activate mitogen-activated protein kinase
kinase 1 (MKK1)1 and consequently the mitogen-activated pro-
tein kinase cascade (2–5).
Raf-1 regulation is a complex process that integrates infor-
mation from multiple signaling pathways. The Raf-1 kinase
domain is in the C-terminal half of the protein. The N-terminal
half of the protein contains two conserved regions termed con-
served region 1 (CR1) and conserved region 2 (CR2) (6) (Fig. 1).
Deletion analysis and point mutations show that the CR1 and
CR2 regions are inhibitory (4, 7, 8). Loading of Ras with GTP
induces the binding of Raf-1 to Ras and the subsequent trans-
location of Raf-1 to the plasma membrane (9–12). This trans-
location is accompanied by an activation of the basal kinase
activity of Raf-1 (13, 14). The Raf-1 kinase is further activated at
the membrane by changes in inter- and intramolecular interac-
tions and phosphorylation events (9, 15–19) (reviewed in Ref. 4).
Raf-1 binds to Ras in a GTP-dependent manner through a
Ras-binding domain (RBD) in the N-terminal region of the CR1
domain of Raf. Mutations in the RBD block Ras binding and
prevent activation by a number of stimuli (10, 11, 20–22). The
RBD binds to Ras through an extensive interface (21, 23).
Residues of the second b sheet and the first a helix of the RBD
contact the Ras effector domain (residues 31–41), and Raf-1 or
Ras mutations that map to this interface block binding.
Ras also interacts with the C-terminal part of the CR1 region
of Raf, the cysteine-rich domain (CRD) (24, 25). The CRD binds
to zinc and to phosphatidylserine as well as Ras (26, 27).
Mutations that disrupt the structure of the CRD reduce bind-
ing to Ras in vitro, suggesting that the RBD and the CRD may
both contribute to Raf-1 binding (25). However, CRD binding to
prenylated Ras is not dependent on GTP, suggesting that the
RBD, not the CRD, is the primary sensor of Ras activity (24, 25,
28, 29). The CRD has another important role; certain muta-
tions in the CRD activate Raf-1 (17, 18, 29, 30). These data
suggest that the CRD is important both for the low activity of
unstimulated Raf-1 and for activation by Ras.
Raf-1 binds to 14-3-3 proteins, HSP90, and p50 (4, 31). 14-3-3
and HSP90 may be involved in the stabilization or activation of
Raf-1 (32–37). 14-3-3 binds to Raf-1 at three characterized
sites. The phosphorylated serines at Ser-259 and Ser-621 rep-
resent regulated 14-3-3- binding sites (38, 39). 14-3-3 also binds
to the cysteine-rich domain in Raf-1 by a different mechanism,
and availability of this 14-3-3- binding site may be activation
state-dependent (29). The regulated nature of these three 14-
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3-3- binding sites presents the possibility that 14-3-3 can bind
to alternative sites during Raf-1 activation (40).
We have recently utilized the yeast two-hybrid system to
identify specificity mutants of Ras that bind other effector
proteins but not Raf-1 (1) (see Table I for the mutations in these
mutants). In the present study, we produced a collection of
random mutations in Raf-1 and used the two-hybrid system to
select mutations that restored Raf-1 binding to these Ras mu-
tants. In one case we found a single mutation in the RBD
(N64L) that directly interacts with the residue that was mu-
tated in the Ras mutant it complements, suggesting structural
complementarity. In all other cases the mutated residue was
either Arg-143 or Lys-144 in the CRD. These mutants have
generally increased interaction with mutant and non-mutant
Ras and are somewhat activated in vivo. These mutations also
decrease the ability of the isolated N-terminal regulatory re-
gion to inhibit the isolated C-terminal kinase domain. We pro-
pose that these mutations decrease an inhibitory interaction
between the N-terminal regulatory region and the C-terminal
kinase domain and expose the Raf-1 N terminus for Ras binding.
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid Screens—The two-hybrid screens in this study
used the L40 reporter strain with the dual reporters HIS3 and lacZ.
The strength of interactions between LexA fusions of Ras mutants
expressed from pBTM116 and VP16 fusions of Raf-1 mutants in pVP16
was measured by examining the extent of color change in filter assays
for b-galactosidase, using 0.75 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-
galactoside in Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl,
1 mM MgSO4). Filters were incubated at 30 °C for 1 h to overnight (41).
Activation of the HIS3 reporter was indicated by plating cells on
minimal media lacking histidine and containing increasing concentra-
tions of 3-aminotriazole, an inhibitor of the HIS3 gene product (41).
Comparisons between transformants were made by plating serial dilu-
tions of cells in drops onto plates in the absence and presence of
increasing concentrations of 3-aminotriazole. The plating efficiency was
calculated, and the HIS3 reporter level was determined to closely relate
to the relative activity of the lacZ reporter assayed in parallel.
Generation and Selection of Human Raf-1 Mutants—The Raf M1
library was generated by regionalized codon mutagenesis of residues
58–70 in Raf-1 (42). The Raf M2 library was generated by random PCR
mutagenesis in the presence of MnCl2 as described elsewhere (1). The
region from residues 1 to 149 (prior to the HindIII site at codon 150) was
then subcloned into a wild-type backbone in pVP16. Both of these
libraries were transfected into the L40 yeast reporter strain along with
V12G Ras and the J10, J25, and J31 Ras mutants in pBTM116 (see
Table I for mutations present in the Ras mutants used). The transfor-
mants were plated onto selective media in the absence of histidine to
select for Raf-1 mutants that had increased binding to the J10, J25, and
J31 Ras mutants. Increased binding was confirmed by b-galactosidase
assays. Plasmids were recovered from the positive clones, and the
clones were retested for binding to the Ras mutants and for binding to
MKK1a. False positives that did not retest and mutants that had lost
the ability to bind to MKK1a were discarded. Mutations were se-
quenced on both strands using dye terminator sequencing.
Each VP16 Raf-1 mutant was then transfected with each LexA Ras
mutant into L40, and the level of binding in the two-hybrid system was
assessed as described above (41).
Protein Expression and Binding Assays—The Raf-CRD (Raf-1 resi-
dues 136–187) and the Ras variants used in the study were expressed
as glutathione S-transferase (GST) fusion proteins and purified. The
Ras mutants were eluted from the glutathione (GSH) beads and bound
to GMP-PNP. The Raf-CRD was cleaved from the GSH beads using
thrombin (26, 27).
The RBD (residues 51–131) was produced as a maltose-binding pro-
tein fusion in Escherichia coli and affinity purified on amylose agarose
and eluted in 20 mM Tris, pH 8, 200 mM NaCl, 0.5 mM EDTA, and 10 mM
maltose.
Enzyme-linked immunosorbent assays were employed to assess the
interactions between the Ras mutants and the isolated Raf-1 CRD and
RBD. The assays were similar to those described elsewhere (28). The
Raf-1 fragments were immobilized on high affinity microtiter plates
(Costar). Nonspecific interactions measured by using blank or MBP-
coated plates (28). All assays were performed twice in triplicate.
14-3-3z Binding Assays—The DNA encoding the Raf-1 mutants were
moved into pBTM116 and transfected into L40 along with pVP16 14-
3-3z. The two-hybrid interaction between 14-3-3z and the Raf-1 mu-
tants was assessed as described above (41).
The DNA encoding 14-3-3z was subcloned into pGEX3x for bacterial
expression. GST and a GST 14-3-3z fusion protein were expressed in E.
coli and affinity purified using GSH-Sepharose. Raf-1 mutants were
subcloned into pCS3MT (43) and expressed in rabbit reticulocyte ly-
sates according to the supplier’s instructions (Promega), in the presence
of [35S]methionine. The reticulocyte lysates were diluted 1:10 in binding
buffer (20 mM Tris 7.5, 1% Triton X-100, 10% glycerol, 50 mM NaF, 100
mM NaCl, 14 mM b-mercaptoethanol), and 5% of the reaction was run on
SDS-polyacrylamide gel electrophoresis. The expression levels of the
Raf-1 proteins were estimated by PhosphorImager analysis. Raf-1 pro-
teins were incubated with 1 mg of GST or GST 14-3-3z on GSH beads in
FIG. 1. Schematic Raf-1 primary structure showing regions where sequence is conserved in the Raf family. The CR1 contains the
RBD and the CRD; the CR2 is rich in threonine and serine residues, and the CR3 contains the kinase domain. Also shown are the N64L, R143W,
R143Q, and K144E mutations.
FIG. 2. Ras specificity mutants were
assessed for binding to the Raf RBD
(A) and CRD (B) in vitro. Fusion pro-
teins were expressed in E. coli and puri-
fied, and binding was determined by
ELISA (see “Experimental Procedures”).
Results are summarized from an assay
done in triplicate. Error bars are not
shown when they were less than 5% of the
mean.
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1 ml of binding buffer for 2 h at 4 °C with end over end shaking. The
beads were precipitated by centrifugation and washed 4 times with 1 ml
of binding buffer. After the final wash, the beads were incubated with
SDS-PAGE Loading buffer and analyzed by electrophoresis and Phos-
phorImager analysis. Similar results were obtained four times.
Enzyme-linked immunosorbent assays were employed to assess the
interactions between the Ras mutants and the isolated Raf-1 CRD
and14-3-3z. The assays were similar to those described elsewhere (29).
The Raf-1 fragments were immobilized on high affinity microtiter
plates (Costar). Nonspecific interactions were measured by using blank
plates (29). All assays were performed twice in triplicate.
Transformation Assays—Focus formation assays were performed as
described (29, 44). All of the plates received 1 mg of RhoA V14G in
pLSXN vector, 1 mg of the Raf-1 mutant in pCS3MT vector, and 18 mg
of sheared calf thymus DNA. To control for the effect of wild-type Raf,
pCS3MT alone was used. The cells were transfected using the calcium
phosphate precipitation method as described (44) and scored for G418
resistance and focus formation as described (44). Each data point pre-
sented is the summary of foci from 12 separate platings of transfected
cells from 3 independent experiments.
Oocyte Injections—Wild-type full-length Raf-1 and Cat Raf con-
structs have been described (15, 45). The Reg Raf construct is described
(46). Mutant Reg Raf constructs were generated by PCR amplification
of Raf-1 residues 1–330 using mutant Raf-1 DNA as template. PCR
products were cloned into the pA vector immediately downstream of the
FLAG epitope tag. Mutations were also made in full-length Raf-1 in the
pA vector by site-directed mutagenesis (Quickchange, Stratagene).
Oocytes were isolated and defolliculated as described previously.
8–12 h after isolation, oocytes were injected with approximately 30 ng
of in vitro transcribed RNA encoding the full-length Raf-1 proteins or
Reg Raf proteins. Oocytes expressing the Reg Raf proteins were then
injected 4–8 h later with RNA encoding Cat Raf (15, 37, 45). The
oocytes were scored for GVBD, as evidenced by the appearance of a
white spot on the animal pole. This observation was verified by manual
dissection of oocytes after fixation in 8% trichloroacetic acid.
Xenopus oocytes were lysed by trituration with a pipette tip in RIPA
buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 2 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, aprotinin (0.15 units/ml),
20 mM leupeptin, 5 mM sodium vanadate). Insoluble material was
pelleted by centrifugation and normalized for protein concentration.
Raf-1, Reg Raf, and Cat Raf protein expression was assessed by West-
ern blot (15, 37, 45).
RESULTS
Characterization of Ras Mutants—We have recently used the
yeast two-hybrid system to identify mutants of activated
(G12V) Ras bind reduced levels of full-length Raf-1 (see Fig. 1
for a schematic of Raf-1) but bind normal levels of two other
Ras effector domain-binding proteins (1). Curiously, these spec-
ificity mutants still bind to the Raf-1 RBD in yeast (Ref. 1, Fig.
3A). To test whether the Ras specificity mutants bind the RBD
in vitro, an ELISA-based assay was used (Fig. 2). The RBD
bound to the J10, J25, and J31 specificity mutants, although
binding was reduced compared with wild-type (G12V) Ras. The
CRD bound to wild type and mutants equally. These results
suggest that the Ras specificity mutations reduce, but do not
prevent, binding to the isolated RBD and have no effect on
binding to the isolated CRD. Binding to full-length Raf-1 is
strongly inhibited (1), however, suggesting that the Raf-1 ki-
nase domain inhibits binding mediated by the RBD and CRD.
Mutations in Raf-1—We used the two-hybrid system to
search for mutations in full-length Raf-1 that increased binding
to the Ras specificity mutants. We expected that mutations in
Raf-1 could increase binding in three ways as follows: by delet-
ing the inhibitory Raf-1 kinase domain, by specifically comple-
menting the Ras mutations, or by relieving the inhibitory effect
of the C-terminal catalytic region. We made two libraries of
random Raf-1 mutants, libraries M1 and M2. In library M1, the
first loop of the RBD (codons 58–70) was mutagenized by
regionalized codon mutagenesis (42). In library M2, codons
1–149 were mutagenized by low stringency PCR. These Raf-1
mutant libraries were transformed into the L40 two-hybrid
reporter strain and screened for interaction with the Ras spec-
ificity mutants. Table I shows that the mutagenesis of Raf-1
increased the frequency of clones in which Ras and Raf-1 in-
teract. Thus, for most combinations, the majority of identified
clones contained mutations that caused increased Raf-1 inter-
action with mutant Ras.
Because truncation of the C terminus of Raf-1 increases
interaction with the Ras mutants (Fig. 3A, compare RIP 7 and
RIP 51 truncation mutants with full-length Raf-1) (1, 10), we
FIG. 3. Interactions between Ras and Raf-1 mutants in yeast. A, the N64L Raf-1 mutant suppresses the J31 Ras mutant but not the J10
or J25 Ras specificity mutants. A b-galactosidase filter assay (5-h development) showing the interaction of wild-type Raf-1, two characterized
truncations of Raf-1 (RIP7 51–178, and RIP51 48–178 (10)), and N64L Raf-1 with G12V Ras, MKK1a, the Rap1A small G protein, and Ras
specificity mutants. Darker color indicates binding. B, R143W and R143Q Raf-1 mutants suppress the J10 and J25 Ras mutants differentially and
have increased binding to G12V Ras. Ten-fold dilutions of saturated cultures of yeast strains containing Ras and Raf-1 mutants were plated either
on selective media containing His or on media lacking His and including 3 mM 3-aminotriazole. Representative of three assays. Increased growth
and colony forming success indicates increased binding. 21, 22, 23, and 24, log10 of dilution. C, R143W, R143Q, and R144E have increased
binding to G12V Ras. A b-galactosidase filter assay (1 h) showing the interaction of wild-type Raf-1, R143Q, R143W, and K144E with G12V Ras.
Darker color indicates stronger interaction.
TABLE I
Effects of mutagenesis on Ras/Raf-1 interaction
Strain L40 yeast cells were transformed with either wild-type (G12V)
Ras or Ras specificity mutants, together with either wild-type Raf-1, the
M1 library, or the M2 library. The frequency of colonies showing inter-
action between Ras and Raf-1 (His-positive phenotype) was calculated
relative to the total number of transformants in each case. Individual
substitutions present in each specificity mutant, J10, J25, and J31,
are shown. Each of these mutants also contains the G12V-activating
mutation.
Ras mutant designation
G12Va J10b J25c J31d
no. interacting clones/104 transformants
Raf-1 WT 104 0.48 0.08 0.60
Raf M1 library 104 0.65 2.6 2.3
Raf M2 library 104 14 3 18.0
a Mutation present is G12V.
b Mutations present are G12V and E31K.
c Mutations present are G12V, Q43E, D54N, and E63K.
d Mutations present are G12V, R41Q, and Y157N.
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screened for truncation mutants using the C-terminal binding
protein and Raf-1 substrate, MKK1. Raf-1 mutants that did not
interact with MKK1 were likely to lack the C terminus and
were discarded. The remaining eight clones were retested to
ensure that all false positives and truncation mutants had been
eliminated. The DNA was then sequenced, and codons 1–149
were recloned into a wild-type Raf-1 background to confirm
that there were no hidden mutations outside of the mu-
tagenized region.
The N64L Raf-1 Mutation—The specificity of the Raf-1 mu-
tants was examined. The only missense mutant identified from
the Raf M1 library was an N64L mutation in Raf-1, isolated
because it increased binding to Ras mutant J31. Raf-1 N64L
interacted with J31 but not J10 or J25 (Fig. 3A, Table II). Raf-1
N64L was the only allele-specific mutant identified. The basis
for this specificity will be discussed below (see “Discussion”).
Raf-1 CRD Mutants—We isolated seven other Raf-1 mutants
from the Raf M2 library that were general suppressors. All of
these mutants had changes in either codons 143 or 144 of Raf-1.
The R143Q mutation was isolated four times, three times using
Ras mutant J10 (once with a secondary T49S mutation), and
once using J31. R143W was isolated once each using J25 and
J31. K144E was isolated once using J10.
The mutations at codons 143 and 144 suppressed J10, J25,
and J31 to different extents, suggesting some level of allelic
specificity (Fig. 3B, Table II). Multiple transformations of bait
and transactivator plasmids gave consistent results. The
R143Q mutant was a good suppressor of J10 and J31 but only a
weak suppressor of J25. On the other hand R143W was a good
suppressor of J25 and J31 but a weak suppressor of J10. The
R144E mutation was a good suppressor of J10 and J31 but not of
J25. Importantly, the three mutations at codons 143 and 144 also
increased the interaction of Raf-1 with wild-type Ras (G12V)
suggesting a general effect on conformation (Fig. 3C, Table II).
Although it is clear that the R143W, R143Q, and K144E muta-
tions are general suppressors of the J10, J25, and J31 Ras mu-
tations, the allelic specificity suggests that there are differ-
ences in the ways that these Raf-1 and Ras mutants interact.
14-3-3 Protein Binding to Raf-1 Mutants—A recent analysis
showed that the isolated Raf-1 CRD binds to 14-3-3 and that a
double mutation in the CRD, R143E/K144E, inhibited binding
(29). To examine the binding of the Raf-1 mutants to 14-3-3z in
the context of full-length Raf-1 protein, 14-3-3z was subcloned
into pVP16, and the Raf-1 mutants were subcloned into
pBTM116. A two-hybrid test showed interaction of Raf-1 with
MKK1 and 14-3-3z but no interaction with VP16 alone. Binding
of 14-3-3z to R143Q, R143W, and K144E Raf-1 mutants was
equal to 14-3-3z binding to wild-type Raf-1 (data not shown). A
GST-14-3-3z fusion protein was then made in E. coli and puri-
fied using glutathione-Sepharose beads. The ability of in vitro
translated Raf-1 protein to bind to the immobilized 14-3-3z was
assessed, and no difference in the ability of 14-3-3z to bind to
wild-type or mutant Raf-1 was seen (Fig. 4A). There are three
characterized binding sites for 14-3-3 in the Raf-1 protein (29,
38). It is possible that 14-3-3 binding to the CRD site of the
R143Q, R143W, and K144E mutant is reduced, as it is for the
R143E/K144E mutant (29), but this reduction may be masked
by continued binding to the two sites outside the CRD. Indeed,
when mutations at codons Arg-143 and Lys-144 (R143E,
K144Q, and R143E/K144E) were examined for in vitro 14-3-3z
FIG. 4. Binding of Raf-1 and CRD mutants to 14-3-3z. A, the
R143W, R143Q and K144E mutations do not affect the in vitro binding
of full-length 35S-labeled Raf-1 to 14-3-3z. Full-length wild-type or mu-
tant Raf-1 was transcribed and translated in vitro. In vitro translations
were incubated by GST alone or GST-14-3-3z, and bound proteins were
detected by SDS-polyacrylamide gel electrophoresis and autoradiogra-
phy. The percentage of binding compared with input into the binding
assay was calculated using a PhosphorImager and is indicated above
each column. B, mutations at codons 143 and 144 reduce Raf-1 CRD
binding to 14-3-3z. Fusion proteins were expressed in E. coli and puri-
fied, and binding was determined by ELISA (see “Experimental Proce-
dures”). Results are summarized from an assay done in triplicate. Error
bars are not shown when they were less than 5% of the mean.
TABLE II
Specificity of Raf-1 suppressors
Mutants of Raf-1 were isolated as suppressors of Ras mutants with
decreased binding to Raf-1. The Ras mutant that was used in the
selection is listed. The Raf-1 mutants were re-transformed with acti-
vated Ras (G12V) and the Ras mutants into the L40 reporter strain, and
the level of two-hybrid interaction was assessed using both the HIS3
and lacZ reporters. The data are summarized with 111 indicating a
very strong interaction, 11 indicating a strong interaction, 1 indicat-
ing a weak interaction, and 2 indicating the lack of an interaction.
Assays not done are signified by ND.
Raf-1 mutant Ras mutant usedin selection G12V J10 J25 J31
Wild type 11 2 2 2
N64L J31 11 2 2 11
R143Qa J10 and J31 111 111 1 111
R143W J25 and J31 111 1 111 111
K144E J10 111 111 11 111
a R143Q was isolated twice using Ras mutant J10, and a double
mutant of Raf-1 T49S/R143Q was identified once with Ras mutant J10.
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binding in the context of the CRD, reduced 14-3-3z binding
relative to the wild-type CRD was seen (Fig. 4B) (29). Thus
general suppressor mutants R143W, R143Q, and K144E are
likely to interfere with 14-3-3 binding to the CRD, but not
14-3-3 binding to other parts of Raf-1.
Increased Activity of Raf-1 Mutants—We tested whether the
143 and 144 Raf-1 CRD mutants were enzymatically activated.
Neither direct in vitro kinase assays nor direct focus assays
revealed any activation (data not shown), but two assays sug-
gested that the mutants are more active than wild-type Raf-1.
The Raf-1 CRD mutants transform NIH 3T3 cells in cooper-
ation with an activated allele of the RhoA small G protein (29).
RhoA G14V or wild-type Raf-1 (data not shown) produce low
numbers of foci if transfected into NIH 3T3 cells on their own.
The numbers of transformed foci increase when activated RhoA
G14V and Raf-1 are transfected together. The K144E, R143Q,
and R143W mutants produce between 3 and 4 times more foci
than wild-type Raf-1, showing that these mutants are activated
(Fig. 5). This level of increase is similar to that reported for the
R143E/K144E double mutant (29).
Activated Raf-1 stimulates cell cycle entry in Xenopus
oocytes and leads to germinal vesicle breakdown (GVBD) (45).
Approximately 100 oocytes were injected with RNA encoding
wild-type, R143W, or K144E mutant Raf-1. The wild-type Raf-1
induced GVBD in very few of the oocytes. In contrast, the
R143W and the K144E mutants both induced GVBD in ;60%
of the oocytes (Fig. 6A). R143Q was not tested. For comparison,
a known activated mutant of Raf-1, the CRM mutant, induced
GVBD in 80% of the oocytes. The expression of the wild-type
and mutant Raf-1 proteins in the oocytes was examined by
Western blot and found to be equal (Fig. 6B).
Reduced Inhibition of the Raf-1 Catalytic Domain by the
Mutant Raf-1 Regulatory Region—To test the basis for the
activation of Raf-1, we measured the effect of the mutations on
the interaction between the N-terminal regulatory region and
the kinase domain. The catalytic domain of Raf-1 (Cat Raf) is
deregulated, and injection of RNA encoding this domain into
oocytes induces GVBD (46). The wild-type Raf-1 regulatory
region (Reg Raf) can inhibit Cat Raf when supplied in trans
(46). This inhibition requires the CRD but not the RBD (46).
Reg Raf proteins containing R143Q, R143W, and R144E mu-
tations did not inhibit Cat Raf-induced GVBD to the same
extent as the wild-type Reg Raf (Fig. 7A), although they are
expressed to an equal or higher level as assessed by Western
blot (Fig. 7B). This reduction in GVBD inhibition by the mutant
Reg Raf leads us to postulate that an inhibitory interaction
between the N-terminal regulatory region of Raf-1 and the
C-terminal catalytic domain of Raf-1 is reduced by mutations in
the CRD. The destabilization of this interaction by these mu-
FIG. 5. Focus formation by Raf-1 mutants in cooperation with Rho A G14V. A, the number of Raf-1/RhoA induced foci relative to
transfection efficiency are indicated. Each data point is a summary of 12 different platings in three independent experiments. B, representative
foci on plates stained with crystal violet induced by G14V RhoA alone, G14V RhoA plus wild-type Raf-1, G14V RhoA plus Raf-1 R143W, G14V RhoA
plus Raf-1 R143Q, and G14V RhoA plus Raf-1 K144E.
FIG. 6. Raf-1 R143W and K144E mutants induce Xenopus
oocyte meiotic maturation. Stage 6 oocytes were injected with 30 ng
of mRNA encoding wild-type, R143W, K144E, or CRM (an activated
control) Raf-1. GVBD was scored 8–20 h after injection by the appear-
ance of a white spot on the animal pole of the oocyte and confirmed by
dissection of the oocytes. A, the percentage of oocytes undergoing GVBD
is indicated by the black bars. The ratio of oocytes undergoing GVBD over
the total number of oocytes injected is displayed above each bar. B,
Western analysis for expression of FLAG tagged Raf-1 in injected oocytes.
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tations would have two effects. It would increase the accessi-
bility of the entire CR1 region for binding to Ras and would also
allow for increased activity of the catalytic domain.
DISCUSSION
We used the two-hybrid system to isolate mutations in Raf-1
that increase binding to Ras specificity mutants (1). We identified
one allele-specific suppressor that compensates for a specific
structural change present in one mutant Ras. The N64L mutant
specifically increases binding to a Ras mutant with an R41Q
mutation. Arg-41 lies at the end of the effector domain. In the
structural model for Ras binding to the RBD (23), the side chain
of Ras Arg-41 interacts with that of Raf-1 Asn-64. It is likely that
replacement of Asn-64 of the RBD with leucine compensates
partly for the substitution of Arg-41 of Ras with glutamine.
We expected that mutations in Raf-1 that allowed for a
relaxation of interdomain interactions would also increase
binding to Ras. This expectation is based on the observation
that Ras binds more weakly to full-length Raf-1 than to the
RBD (10), suggesting that the Raf-1 kinase domain interferes
with Ras binding to the RBD. Furthermore, the Ras specificity
mutants have reduced binding to Raf-1 but significant binding
to the RBD (Fig. 3A, Ref. 1), unlike some Ras effector domain
mutants. Because the Ras specificity mutants still interact
with the RBD and CRD, we predicted that mutations in full-
length Raf-1 that expose the RBD and CRD would be general
suppressors of the Ras mutants.
Mutations at codons 143 and 144 were repeatedly isolated in
this screen as general suppressors of the Ras specificity mu-
tants. The R143W, R143Q, and K144E mutants increase bind-
ing to wild-type activated Ras and to the J10, J25, and J31
specificity mutants (Fig. 3, B and C). The increased interac-
tions of these mutants with wild-type Ras suggest an increased
exposure of Ras-binding surfaces of the RBD, or the CRD, or
both domains. However, there is some allelic specificity, imply-
ing that the CRD also contacts Ras directly (Fig. 3B, Table II).
In particular the R143W mutant interacts better with J10 and
J31 than J25, and the R143Q and K144E mutants interact
better with J25 and J31 than J10.
Mutations in the CRD may increase Ras access to the RBD
and CRD and simultaneously interfere with Ras-CRD binding.
The balance between these effects could differ according to the
specific mutant combination. The R143W mutation is non-
conservative and may affect CRD folding, whereas R143Q and
K144E are more conservative. Since the J10 Ras mutant has a
lower affinity than J25 or J31 for RBD binding (Fig. 2A), it may
rely more on the CRD for binding and is more adversely af-
fected by the non-conservative R143W than the conservative
R143Q or K144E Raf-1 mutations. The J25 and J31 Ras mu-
tants rely less on the CRD for binding, and the increased
exposure of the RBD and CRD in the R143W Raf-1 mutant may
outweigh negative effects on Ras-CRD binding.
Residues 143 and 144 are prominently displayed on an ex-
posed b strand within the CRD (27) and are conserved across
the Raf family of protein kinases. Due to the surface localiza-
tion and the charged nature of these residues, they may be
involved in intermolecular or intramolecular interactions. A
R143E/K144E double mutant, reversing the charge of this loop,
was characterized previously (29). Like the R143Q, R143W,
and K144E mutants isolated here, the R143E/K144E mutant
can transform cells in cooperation with RhoA G14V. In isola-
tion, the R143E/K144E CRD lost binding to 14-3-3z in vitro in
FIG. 7. Inhibition of Cat Raf by Reg Raf is decreased by muta-
tion of residues 143 and 144. Wild-type and mutant Reg Raf mRNAs
(30 ng) were injected into oocytes. After 4–8 h Cat Raf was injected, and
GVBD was scored 8–20 h later by the appearance of a white spot on the
animal pole and confirmed by dissection. A, the percentage of oocytes
undergoing GVBD is represented by the black bars, and the ratio of
oocytes undergoing GVBD over the total number of oocytes injected is
displayed above each bar. B, Western analysis of the expression of
FLAG-tagged Reg Raf and untagged Cat Raf.
FIG. 8. A model for Raf-1 activation. Raf-1 is in an equilibrium
between a closed (inactive) and open (active) conformation. The N64L
mutation lies right at the interface between the RBD-binding site on
Raf-1 for Ras and affects this interaction. The R143Q, R143W, and
K144E mutations are within the CRD and affect the negative regula-
tory interaction between the N-terminal regulatory region and the
C-terminal kinase domain. Consequently the open conformation is sta-
bilized, allowing better access for Ras binding and higher Raf-1 activity.
The negative regulatory interaction between the N-terminal regulatory
region and the C-terminal kinase domain could be either intramolecu-
lar or intermolecular, perhaps involving 14-3-3 proteins.
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the absence of any loss of Ras binding (29), leading to the
proposal that 14-3-3 binding to the CRD negatively regulates
Raf-1. We failed to detect any reduction of 14-3-3z binding to
full-length R143Q, R143W, and R144E mutants of Raf-1 either
in the two-hybrid system or in vitro. However, in vitro binding
studies with other mutations of codons 143 and 144 did reduce
14-3-3 binding to the isolated CRD (Fig. 4). Thus the effects of
Arg-143 and Lys-144 substitutions on Ras binding and Raf-1
activity could be mediated in part by a shift of 14-3-3-binding
sites from the CRD to other parts of the Raf-1 molecule.
Mutation of Arg-143 or Lys-144 partly activates Raf-1. Acti-
vation was too small to be detected by most assays used. How-
ever, all three mutants are activated in a sensitive focus for-
mation assay in cooperation with RhoA G14V, and the R143W
and K144E mutants are activated in the GVBD induction assay
when compared with wild-type Raf-1. As the N-terminal regu-
latory region (Reg Raf) can inhibit the function of the catalytic
region (Cat Raf) of Raf-1 assayed in Xenopus oocytes (46), we
examined the effects of the R143W, R143Q, and R144E mutant
Reg Raf on Cat Raf GVBD. All three of these mutations prevent
Reg Raf from inhibiting Cat Raf.
These results fit a model that proposes a mutually inhibitory
interaction between the N-terminal regulatory region and the
catalytic region (Fig. 8) (46). This interaction both inhibits
catalysis by the Raf-1 kinase domain and limits access by Ras
to the RBD and CRD regions. Mutations that interfere with the
inhibitory interaction are thus predicted to both activate the
Raf-1 kinase domain and increase the binding of Ras to Raf-1
RBD and CRD. Site-directed mutations in the CRD can inter-
fere with the inhibitory interaction (46), implicating the CRD
in maintaining the inactive state. The present isolation of CRD
mutations at codons 143 and 144 in a random screen further
implicates the CRD, and residues 143 and 144 in particular, in
negative regulation of Raf-1. However, our data do not address
whether the interaction between the CRD and the kinase do-
main is direct or indirect. The CRD, through residues 143 and
144, could contact the kinase domain. Alternatively, an indirect
interaction could be mediated by another protein X (Fig. 8). One
candidate for X is 14-3-3, since mutations of residues 143 and 144
reduce Raf-1 CRD binding to 14-3-3 in vitro (Fig. 4B) (29).
White et al. (47) used a Ras effector domain mutant (E37G),
which did not bind to Raf-1, to isolate Raf-1 mutants that
restored binding. Like the suppressor mutants isolated in the
present study, the suppressing mutation was not in the RBD.
However, the Raf-1 mutation suppressing Ras E37G was in the
CR2 region, not the CRD (47). As Ras E37G binds to the isolated
Raf-1 RBD (data not shown), these data support the mutual
inhibition model (Fig. 8), in which the CR2 domain of Raf-1 also
contributes to the inhibited conformation. Interestingly, the mu-
tated residue, Ser-257, is within one of the known 14-3-3-binding
sites on Raf-1, again implicating 14-3-3 in inhibitory interactions.
The model for Raf-1 regulation resembles that proposed for
Byr2, a Ras-regulated kinase from Schizosaccharomyces pombe
(48). Like Raf-1, Byr2 has a C-terminal catalytic domain and an
N-terminal regulatory region. Byr2 activation involves the
binding of the Ras homolog, Ras1, the scaffolding protein Ste4,
and phosphorylation by the protein kinase Shk. The N-termi-
nal regulatory region (Reg Byr2) binds to the catalytic domain
(Cat Byr2), and binding is disrupted by specific mutations (48).
These mutations increase binding to Ras1 and Ste4 and acti-
vate the Byr2 kinase domain. Phosphorylation of the N termi-
nus by Shk1 antagonized the interaction of Reg Byr2 with Cat
Byr2 and also contributes to Byr2 activation. Inhibitory inter-
actions between regulatory and catalytic regions of protein
kinases is a common theme, and it will be important to uncover
the structural basis in each case.
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